Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giants
The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins
Add BT as a preferred source
[SINGAPORE] A quarter-century after the Republic ambitiously set out to build biomedical sciences into an economic pillar, it has yet to produce a home-grown champion on the scale of Denmark’s Novo Nordisk or the United States’ Moderna.
The local ecosystem boasts a solid foundation of research institutions, and a healthy pipeline of startups spanning pre-clinical to late-stage development. Yet, it still has not come up with a blockbuster drug nor a globally recognised brand name that manages a pipeline from the laboratory to the market.
It has come close, though. In 2022, Tessa Therapeutics emerged as a rising star, securing US$126 million in Series A funding to advance clinical development of its immune cell therapies for cancer.
TRENDING NOW
Asia-Pacific aviation: is up really the only way?
Russia’s ‘pivot to Asia’ takes a turn as it prioritises ties with isolated regimes over bigger economies
Why disciplined stewardship matters when managing wealth in uncertain markets
More than 15,000 sign up for national accounting body’s AI programme in two months
